We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FASENRA (AstraZeneca Pty Ltd)
Product name
FASENRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
215 working days (255)
Active ingredients
benralizumab
Registration type
NCE/NBE
Indication
FASENRA (solution for injection) is indicated as add-on therapy in patients aged 12 years and over with severe eosinophilic asthma (blood eosinophil count ≥300 cells/µL or ≥150 cells/µL if on oral corticosteroid treatment).